ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + Capecitabine
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma
Trial Timeline
Oct 16, 2025 → Jan 31, 2028
NCT ID
NCT07024615About ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + Capecitabine
ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + Capecitabine is a phase 1 stage product being developed by Astellas Pharma for Pancreatic Ductal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07024615. Target conditions include Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Ductal Adenocarcinoma were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07024615 | Phase 1 | Recruiting |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma